Entero Healthcare Solutions Limited has informed the Exchange about Amalgamation/Merger

Nclt Scheme FiledStrategic Transactions View source PDF Explain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹1217.20

prior close

₹1209.10

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.6%+2.8% vs market

Retailing peers, median of 52sector · industry level+0.7%+3.7% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 3.7 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+2.4

15m

+2.2

30m

+2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+1.6+2.8+0.7+3.7

Next day

+0.3+1.5-1.2+0.2+0.2

+0.2+0.0+0.2-0.9+1.2

-1.2-3.0+1.9-2.7+1.6

-2.9-2.4-0.5-3.2+0.3

-4.4-2.1-2.3-4.0-0.4

-2.2-3.8+1.6-4.5+2.3

15d

-1.5-0.0-1.4-3.2+1.7

-8.9-1.0-7.9-5.5-3.4

-0.6+6.5-7.1-3.7+3.1

+2.6+10.2-7.5-2.4+5.0

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 52Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Regional Director, Southern Region, Chennai, Ministry of Corporate Affairs, confirmed the Scheme of Amalgamation under Section 233 of the Companies Act, 2013. The scheme involves merger of two wholly-owned subsidiaries - Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited - into Rada Medisolutions Private Limited (Transferee Company). The appointed date was April 15, 2025, and the confirmation order was received on May 5, 2026. Both transferor companies are engaged in pharmaceutical distribution and marketing. Since both are wholly owned subsidiaries, no new shares will be issued and investments will be cancelled. Post-merger, the authorized share capital of the Transferee Company increases to Rs. 1,35,00,000.

Likely market impact

The direct impact on Entero Healthcare Solutions is minimal as this involves internal subsidiary restructuring. The merger may lead to operational efficiencies and cost savings in the pharma distribution business under Rada Medisolutions over time.